Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?

Last month, the company announced robust financial results for the first quarter of 2024. It also provided an update on its promising set of pipeline candidates, which are being developed as the next generation of precision medicines for the treatment of cancer. Several clinical milestones are expected later in 2024. This may have been driving the share price rally. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong ...